Skip to main content
. 2022 May 15;77(1):239–255. doi: 10.1002/hep.32538

FIGURE 2.

FIGURE 2

Intestine‐specific Ppara disruption attenuated obesity and NASH. (A,B) Ppara ∆IE and Ppara fl/fl mice were fed an HFD for 12 weeks (n = 8). (A) Representative H&E staining and Oil Red O staining; scale bar 100 µm. (B) Liver weight, liver index, hepatic TG and TC, serum ALT, TC, TG, and NEFA. (C,D) Ppara ∆IE,ERT2 and Ppara fl/fl mice were fed an HFD for 18 weeks and injected with tamoxifen for the last 8 weeks (n = 5). (C) Experimental scheme, liver weight and index, hepatic TG and TC, and serum ALT, TC, TG, and NEFA. (D) H&E and Oil Red O staining; scale bar 100 µm. (E,F) Ppara ∆IE and Ppara fl/fl mice were fed a HFCFD for 21 weeks (n = 8). (E) Liver weight and index; hepatic TG and TC; serum ALT, TC, TG, and NEFA; and hepatic mRNA levels of fibrogenesis‐ and inflammation‐related genes. (F) Representative H&E, Oil Red O, and Sirius Red staining; scale bar 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001